Immunotherapy

DRUG CLASS:

Immunotherapy

News alerts, weekly reports and conference planners

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials ELCC 2023 - 1 week (New C3) Immunotherapy Sensitive : B ELCC 2023 - 1wk	Immunotherapy Sensitive: B - Late Trials ELCC 2023 - 1 week Immunotherapy Sensitive : B ELCC 2023 - 1 week - (New C3)
CTSL overexpression	Lung Adenocarcinoma	CTSL overexpression	Lung Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials ELCC 2023 - 1 week (New C3) Immunotherapy Sensitive : C3 ELCC 2023 - 1wk	Immunotherapy Sensitive: C3 – Early Trials ELCC 2023 - 1 week Immunotherapy Sensitive : C3 ELCC 2023 - 1 week - (New C3)
ENO1 elevation	Non Small Cell Lung Cancer	ENO1 elevation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ELCC 2023 - 1 week (New C3) Immunotherapy Sensitive : C3 ELCC 2023 - 1wk	Immunotherapy Sensitive: C3 – Early Trials ELCC 2023 - 1 week Immunotherapy Sensitive : C3 ELCC 2023 - 1 week - (New C3)
TP53 mutation + PD-L1 expression	Non Small Cell Lung Cancer	TP53 mutation + PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ELCC 2023 - 1 week (New C3) Immunotherapy Sensitive : C3 ELCC 2023 - 1wk	Immunotherapy Sensitive: C3 – Early Trials ELCC 2023 - 1 week Immunotherapy Sensitive : C3 ELCC 2023 - 1 week - (New C3)
HLA-A underexpression + PD-L1 expression	Non Small Cell Lung Cancer	HLA-A underexpression + PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials ELCC 2023 - 1 week (New C3) Immunotherapy Resistant : C3 ELCC 2023 - 1wk	Immunotherapy Resistant: C3 – Early Trials ELCC 2023 - 1 week Immunotherapy Resistant : C3 ELCC 2023 - 1 week - (New C3)
TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	TMB-H + PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 AACR 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Sensitive : C3 AACR 2023 - 2 weeks - (New C3)
KRAS G12A	Non Small Cell Lung Cancer	KRAS G12A	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Cancer - 2 weeks (New C3) Immunotherapy Resistant : C3 Cancer - 2wk	Immunotherapy Resistant: C3 – Early Trials Cancer - 2 weeks Immunotherapy Resistant : C3 Cancer - 2 weeks - (New C3)
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Cancer - 2 weeks (New C3) Immunotherapy Sensitive : C3 Cancer - 2wk	Immunotherapy Sensitive: C3 – Early Trials Cancer - 2 weeks Immunotherapy Sensitive : C3 Cancer - 2 weeks - (New C3)
PD-L1 overexpression	Triple Negative Breast Cancer	PD-L1 overexpression	Triple Negative Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks (New D) Immunotherapy Sensitive : C3 AACR 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Sensitive : C3 AACR 2023 - 2 weeks - (New D)
SETD2 mutation	Renal Cell Carcinoma	SETD2 mutation	Renal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 AACR 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Sensitive : C3 AACR 2023 - 2 weeks - (New C3)
ACTA2 overexpression	Gastric Cancer	ACTA2 overexpression	Gastric Cancer	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Resistant : C3 AACR 2023 - 2wk	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Resistant : C3 AACR 2023 - 2 weeks - (New C3)
VEGFB overexpression	Gastric Cancer	VEGFB overexpression	Gastric Cancer	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Resistant : C3 AACR 2023 - 2wk	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Resistant : C3 AACR 2023 - 2 weeks - (New C3)
VEGFA overexpression	Gastric Cancer	VEGFA overexpression	Gastric Cancer	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Resistant : C3 AACR 2023 - 2wk	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Resistant : C3 AACR 2023 - 2 weeks - (New C3)
KRAS mutation + PD-L1 expression	Biliary Tract Cancer	KRAS mutation + PD-L1 expression	Biliary Tract Cancer	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 AACR 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Sensitive : C3 AACR 2023 - 2 weeks - (New C3)
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Resistant : C3 AACR 2023 - 2wk	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Resistant : C3 AACR 2023 - 2 weeks - (New C3)
AXL overexpression + EGFR mutation	Non Small Cell Lung Cancer	AXL overexpression + EGFR mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Resistant : C3 AACR 2023 - 2wk	Immunotherapy Resistant: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Resistant : C3 AACR 2023 - 2 weeks - (New C3)
IDO1 expression	Non Small Cell Lung Cancer	IDO1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 AACR 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials AACR 2023 - 2 weeks Immunotherapy Sensitive : C3 AACR 2023 - 2 weeks - (New C3)
CD276 expression	Clear Cell Renal Cell Carcinoma	CD276 expression	Clear Cell Renal Cell Carcinoma	Immunotherapy Resistant: C3 – Early Trials Diagn Pathol - 3 weeks (New C3) Immunotherapy Resistant : C3 Diagn Pathol - 3wk	Immunotherapy Resistant: C3 – Early Trials Diagn Pathol - 3 weeks Immunotherapy Resistant : C3 Diagn Pathol - 3 weeks - (New C3)
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	Immunotherapy Sensitive: A2 - Guideline Immunotherapy Sensitive : A2	Immunotherapy Sensitive: A2 - Guideline Immunotherapy Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	Immunotherapy Sensitive: A2 - Guideline Immunotherapy Sensitive : A2	Immunotherapy Sensitive: A2 - Guideline Immunotherapy Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	Immunotherapy + VEGFR inhibitor Sensitive: A2 - Guideline Immunotherapy + VEGFR inhibitor Sensitive : A2	Immunotherapy + VEGFR inhibitor Sensitive: A2 - Guideline Immunotherapy + VEGFR inhibitor Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	Immunotherapy + Tyrosine kinase inhibitor Sensitive: A2 - Guideline Immunotherapy + Tyrosine kinase inhibitor Sensitive : A2	Immunotherapy + Tyrosine kinase inhibitor Sensitive: A2 - Guideline Immunotherapy + Tyrosine kinase inhibitor Sensitive : A2
TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	TMB-H + PD-L1 overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
TMB-H	Solid Tumor	TMB-H	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
MUC16 mutation	Non Small Cell Lung Cancer	MUC16 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ARID1A mutation	Non Small Cell Lung Cancer	ARID1A mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
TP53 mutation + KRAS mutation	Non Small Cell Lung Cancer	TP53 mutation + KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
MUC16 mutation	Melanoma	MUC16 mutation	Melanoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ARID1B mutation	Non Small Cell Lung Cancer	ARID1B mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KMT2C mutation + TP53 mutation	Non Small Cell Lung Cancer	KMT2C mutation + TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma	HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ARID2 mutation	Non Small Cell Lung Cancer	ARID2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
PBRM1 mutation	Clear Cell Renal Cell Carcinoma	PBRM1 mutation	Clear Cell Renal Cell Carcinoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B
PD-L1 underexpression	Esophageal Adenocarcinoma	PD-L1 underexpression	Esophageal Adenocarcinoma	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B	Immunotherapy Resistant: B - Late Trials Immunotherapy Resistant : B
ATR mutation	Solid Tumor	ATR mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ERCC4 mutation	Solid Tumor	ERCC4 mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
PARP1 mutation	Solid Tumor	PARP1 mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
RAD50 mutation	Solid Tumor	RAD50 mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
NBN mutation	Solid Tumor	NBN mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
TERT mutation	Solid Tumor	TERT mutation	Solid Tumor	Immunotherapy Sensitive: C2 – Inclusion Criteria Immunotherapy Sensitive : C2	Immunotherapy Sensitive: C2 – Inclusion Criteria Immunotherapy Sensitive : C2

Immunotherapy

Immunotherapy

Associations(591)

Associations
(591)